Trial Profile

Phase 2 and Biomarker Trial of Anti-TIGIT and Anti-PDL1 in Patients With Recurrent Glioblastoma

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 31 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atezolizumab (Primary) ; Tiragolumab (Primary)
Indications Glioblastoma
Focus Therapeutic Use

Most Recent Events

27 Dec 2024 Status changed from not yet recruiting to withdrawn prior to enrolment. (Reason the study was stopped: Other - Protocol moved to Disapproved )
08 Nov 2024 Planned initiation date changed from 25 Oct 2024 to 30 Apr 2025.
01 Aug 2024 Planned initiation date changed from 21 Jun 2024 to 25 Oct 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com